RxDoctor Payments Data

Larry Tamburro, MD

Family Medicine · Chandler, AZNPI 1174504930

Payments from drug & device makers

$10,236in general payments, 2019–2025

Across 568 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • AbbVie$1K
  • Lilly USA, LLC$775
  • Boehringer Ingelheim$645
  • Pfizer$514
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$10,13499%
  • Education$1021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk76$1,159
AstraZeneca25$1,114
AbbVie(2 entities)62$1,059
Lilly USA, LLC47$775
Boehringer Ingelheim34$645
Pfizer41$514
Amgen(2 entities)26$427
Johnson & Johnson(2 entities)26$361
GSK18$344
Merck19$295
Astellas Pharma US Inc9$245
Abbott13$236
Novartis11$198
Biohaven Pharmaceutical Holding Company Ltd.4$172
Eisai Inc.8$157
Exact Sciences9$145
Antares Pharma, Inc.10$144
Esperion Therapeutics, Inc.8$135
Dexcom, Inc.6$131
Sanofi-aventis U.S. LLC9$122
Amarin Pharma, Inc.7$117
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC7$114
Gilead5$105
Bayer7$94
Lucid Diagnostics Inc.2$92
Clarus Therapeutics Inc.6$85
Teva Pharmaceuticals USA, Inc.6$84
IBSA Pharma Inc.3$80
Biohaven Pharmaceuticals, Inc.5$74
Sanofi Pasteur Inc.3$60
Impulse Dynamics (USA) Inc.3$55
Topcon Healthcare Solutions, Inc.1$49
Dynavax Technologies Corporation3$48
Medtronic(2 entities)3$48
Corcept Therapeutics2$45
Kowa Pharmaceuticals America, Inc.3$44
Mylan Specialty L.p.3$38
Takeda Pharmaceuticals U.S.A., Inc.2$36
Nestle Healthcare Nutrition Inc.2$34
Tolmar, Inc.2$34
Axsome Therapeutics, Inc.2$33
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$33
Upsher-smith Laboratories LLC2$31
Phathom Pharmaceuticals, Inc.2$30
Ardelyx, Inc.1$29
Currax Pharmaceuticals LLC2$29
Scilex Pharmaceuticals Inc.2$29
Aimmune Therapeutics, Inc.1$26
Hologic Sales And Service, LLC1$25
Vivus LLC2$24
Sumitomo Pharma America, Inc.1$23
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$21
Vanda Pharmaceuticals Inc.1$19
Edwards Lifesciences1$17
Teleflex LLC1$17
Aytu Biopharma, Inc.1$16
Biotronik Inc.1$16
Idorsia Pharmaceuticals US Inc1$15
Paratek Pharmaceuticals, Inc.1$14
Boston Scientific1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,236 in reported general payments places this provider in the 90th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$142,905
Medicare patients
385
Services billed
1,934

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide152$185,578
EliquisApixaban101$89,621
JardianceEmpagliflozin89$87,676
MounjaroTirzepatide73$86,841
FarxigaDapagliflozin Propanediol64$56,040
TrulicityDulaglutide15$39,592
LinzessLinaclotide52$36,136
JanuviaSitagliptin Phosphate23$33,165
ProliaDenosumab16$27,896
VraylarCariprazine Hcl12$16,882
GemtesaVibegron22$16,823
Tresiba Flextouch U-100Insulin Degludec23$13,252
VascepaIcosapent Ethyl21$11,550
MyrbetriqMirabegron17$10,968
Atorvastatin Calcium798$6,477

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,159$185,578152 claims
Lilly USA, LLCMounjaro, Trulicity$775$126,43388 claims
PfizerEliquis$514$89,621101 claims
Boehringer IngelheimJardiance$645$87,67689 claims
AstraZenecaFarxiga, Symbicort$1,114$59,88076 claims
AbbVieLinzess, Vraylar, Synthroid$1,059$57,515113 claims
MerckJanuvia$295$33,16523 claims
AmgenProlia$427$27,89616 claims
Sumitomo Pharma America, Inc.Gemtesa$23$16,82322 claims
Astellas Pharma US IncMyrbetriq$245$10,96817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →